The US Food and Drug
Administration (FDA) has approved
Topamax (topiramate) for migraine
prevention in adolescents aged 12
to 17 years of age.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 01 Apr 14 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Apr 14
EBOS says it expects to increase its underlying earnings during the remainder of the current financial year, with further growth forecast into 2019/20 “as we commence servicing the Chemist Warehouse contract volumes”.